Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP435569.RAk7aNgJ587cHr2oxeatByvFHTU4VPeW0apDcTshfL2TI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP435569.RAk7aNgJ587cHr2oxeatByvFHTU4VPeW0apDcTshfL2TI130_assertion type Assertion NP435569.RAk7aNgJ587cHr2oxeatByvFHTU4VPeW0apDcTshfL2TI130_head.
- NP435569.RAk7aNgJ587cHr2oxeatByvFHTU4VPeW0apDcTshfL2TI130_assertion description "[However, a recent breakthrough indicates clinical efficacy of a drug stimulating the metabotropic glutamate receptor II, LY2140023, which has improved efficacy for negative and cognitive symptoms of schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP435569.RAk7aNgJ587cHr2oxeatByvFHTU4VPeW0apDcTshfL2TI130_provenance.
- NP435569.RAk7aNgJ587cHr2oxeatByvFHTU4VPeW0apDcTshfL2TI130_assertion evidence source_evidence_literature NP435569.RAk7aNgJ587cHr2oxeatByvFHTU4VPeW0apDcTshfL2TI130_provenance.
- NP435569.RAk7aNgJ587cHr2oxeatByvFHTU4VPeW0apDcTshfL2TI130_assertion SIO_000772 18759551 NP435569.RAk7aNgJ587cHr2oxeatByvFHTU4VPeW0apDcTshfL2TI130_provenance.
- NP435569.RAk7aNgJ587cHr2oxeatByvFHTU4VPeW0apDcTshfL2TI130_assertion wasDerivedFrom befree-20150227 NP435569.RAk7aNgJ587cHr2oxeatByvFHTU4VPeW0apDcTshfL2TI130_provenance.
- NP435569.RAk7aNgJ587cHr2oxeatByvFHTU4VPeW0apDcTshfL2TI130_assertion wasGeneratedBy ECO_0000203 NP435569.RAk7aNgJ587cHr2oxeatByvFHTU4VPeW0apDcTshfL2TI130_provenance.